Qiagen Licenses Reagent Tech to Kreatech Biotechnology as It Plots More OEM Deals | GenomeWeb

Qiagen last week took another step towards making its technology broadly accessible to microarray users by announcing a non-exclusive licensing agreement with array manufacturer Kreatech Biotechnology.

The deal underscores Qiagen's strategy to leave the microarray reagent kit market for other players to compete in as it continues to invest in diagnostics and RT-PCR technologies, according to a company official.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.